Mobility, dexterity, vision, cognition: MSCopilot® measures the impact of multiple sclerosis through digital self-assessment

Predicting disability level in multiple sclerosis using MSCopilot®: a real-world post-market surveillance study

In June 2025, at the EAN Congress in Helsinki, Finland, we presented the results of a post-market surveillance study conducted in a French cohort.

This study demonstrates that our MSCopilot® software can assess disability levels in people with multiple sclerosis (MS) in real life.

The correlation of our digital biomarkers with the EDSS (Expanded Disability Status Scale) confirms the clinical reliability of our device for potential daily monitoring.